The latest price target for ENDRA Life Sciences (NASDAQ:NDRA) was reported by Ascendiant Capital on June 7, 2024. The analyst firm set a price target for $8.00 expecting NDRA to rise to within 12 months (a possible 53.85% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for ENDRA Life Sciences (NASDAQ:NDRA) was provided by Ascendiant Capital, and ENDRA Life Sciences maintained their buy rating.

There is no last upgrade for ENDRA Life Sciences

There is no last downgrade for ENDRA Life Sciences.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ENDRA Life Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ENDRA Life Sciences was filed on June 7, 2024 so you should expect the next rating to be made available sometime around June 7, 2025.

While ratings are subjective and will change, the latest ENDRA Life Sciences (NDRA) rating was a maintained with a price target of $10.00 to $8.00. The current price ENDRA Life Sciences (NDRA) is trading at is $5.20, which is out of the analyst’s predicted range.